| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1517/14740338.2014.959489 |
| P698 | PubMed publication ID | 25244582 |
| P50 | author | Javier P Gisbert | Q37829251 |
| María Chaparro | Q55602557 | ||
| P2093 | author name string | María Chaparro | |
| P2860 | cites work | European evidenced-based consensus on reproduction in inflammatory bowel disease | Q37814564 |
| The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics | Q37820898 | ||
| Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease. | Q37845884 | ||
| TNF-α and the development of the neonatal immune system: implications for inhibitor use in pregnancy | Q37862067 | ||
| Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease | Q38113455 | ||
| A novel Fc gamma R-defined, IgG-containing organelle in placental endothelium | Q40388429 | ||
| Defective Peyer's patch organogenesis in mice lacking the 55-kD receptor for tumor necrosis factor | Q42943618 | ||
| Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. | Q44144568 | ||
| Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn | Q44677102 | ||
| Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery | Q44786822 | ||
| Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. | Q46015179 | ||
| A 24-year-old pregnant woman with inflammatory bowel disease. | Q46028158 | ||
| Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure | Q46164590 | ||
| Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. | Q46531976 | ||
| Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy | Q47837061 | ||
| Th1 and Th2 cytokine profiles in recurrent aborters with successful pregnancy and with subsequent abortions. | Q52934788 | ||
| Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. | Q53122367 | ||
| Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. | Q54110885 | ||
| Breastfeeding and the Use of Human Milk | Q54152651 | ||
| Dynamics of immunoglobulins at the feto-maternal interface | Q22305976 | ||
| Management of inflammatory bowel disease in pregnancy | Q26865914 | ||
| Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial | Q28202166 | ||
| Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial | Q28202504 | ||
| Infliximab maintenance therapy for fistulizing Crohn's disease | Q28246982 | ||
| Infliximab for induction and maintenance therapy for ulcerative colitis | Q28285876 | ||
| Infliximab for the treatment of fistulas in patients with Crohn's disease | Q33860666 | ||
| The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations | Q34152778 | ||
| Ex vivo human placenta models: transport of immunoglobulin G and its subclasses | Q35172877 | ||
| Survival in colorectal cancer: impact of body mass and exercise | Q35760804 | ||
| Optimizing anti-TNF treatment in inflammatory bowel disease | Q35787448 | ||
| Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease | Q36072580 | ||
| Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry | Q36223905 | ||
| Drug therapy for inflammatory bowel disease in pregnancy and the puerperium | Q36949280 | ||
| Pregnancy and breastfeeding in patients with Crohn's disease | Q37073424 | ||
| Management of inflammatory bowel disease in the pregnant patient | Q37103320 | ||
| Inflammatory bowel disease and pregnancy: evidence, uncertainty and patient decision-making | Q37224385 | ||
| Is infliximab safe to use while breastfeeding? | Q37265629 | ||
| Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease | Q37554366 | ||
| An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies | Q37559465 | ||
| Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding | Q37626638 | ||
| Inflammatory bowel disease and pregnancy: report of two cases treated with infliximab and a review of the literature | Q37776632 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammatory bowel diseases | Q917447 |
| P304 | page(s) | 1749-1762 | |
| P577 | publication date | 2014-09-22 | |
| P1433 | published in | Expert Opinion on Drug Safety | Q5421206 |
| P1476 | title | How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease? | |
| P478 | volume | 13 |
| Q38707864 | A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease |
| Q41990807 | European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ('Exit Strategies') in Inflammatory Bowel Disease. |
| Q38527999 | Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. |
Search more.